Research Paper Volume 14, Issue 12 pp 5153—5162

Figure 4. VEGFA is critical for miR-613-mediated suppression of gastric cancer under matrine treatment. (A) TargetScan shows that VEGFA is a potential target of miR-613. (B) VEGFA mRNA levels were detected by the RT-qPCR in N87 cells transfected with the NC mimic, miR-613 mimic, NC inhibitor, or miR-613 inhibitor. ^**P < 0.01, ^***P < 0.001. (C) VEGFA mRNA levels were detected by the RT-qPCR in N87 cells transfected with sh-NC, sh-NUTM2A-AS1-1 or sh-NUTM2A-AS1-2. ^***P < 0.001. (D) VEGFA expression levels were determined by the RT-qPCR in N87 cells transfected with pcDNA3.1 or pcDNA3.1-VEGFA. ^***P < 0.001. (E) The MTT assay was used to evaluate the viability of N87 cells transfected with the NC mimic, miR-613 mimic, or miR-613 mimic plus VEGFA under matrine treatment. ^*P < 0.05, ^**P < 0.01. (F, G) Cell colonies of N87 cells transfected with the NC mimic, miR-613 mimic, or miR-613 mimic plus VEGFA under matrine treatment. Scale bar, 5 μm. ^**P < 0.01, ^***P < 0.001. (H, I) The apoptosis of N87 cells transfected with the NC mimic, miR-613 mimic, or miR-613 mimic plus VEGFA under matrine treatment was examined by the TUNEL assay. Scale bar, 5 μm. ^*P < 0.05, ^***P < 0.001. VEGFA, vascular endothelial growth factor A; miR, microRNA; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; NC, negative control; TUNEL, terminal deoxynucleotidyl transferase dUTP nick-end labeling.